This study aims to investigate whether DCB angioplasty, compared to statin-based medical treatment alone, will lead to more reduction in plaque lipid burden as assessed by near infrared spectroscopy (NIRS) at 6-9 months following the index procedure.
A large lipid core is the hallmark of coronary plaques at risk of rupture and subsequent atherothrombosis. Although statin-based medical treatment is known to regress and stabilize lipid-rich coronary plaques, it takes time for such beneficial effects to appear. This study aims to investigate whether DCB angioplasty can effectively modify de novo coronary atherosclerotic plaque and lead to reduction in plaque lipid burden as assessed by near infrared spectroscopy (NIRS) at 6-9 months following the index procedure.
Study Type
OBSERVATIONAL
Enrollment
65
DCB angioplasty will be performed in accordance with the recent recommendations. Specifically, aggressive lesion predilation (balloon-to-artery ratio: 0.8 to 1.2) using either a plain balloon or a scoring balloon will be performed.
Korea University Ansan Hospital
Ansan-si, Gyeonggi-do, South Korea
RECRUITINGDifference of serially-assessed lipid core burden index (LCBI) change between DCB-treated lesion vs. medically-treated lesion
ΔLCBI: NIRS-assessed changes in LCBI between baseline and follow-up.
Time frame: 6~9 month
Difference of serially-assessed plaque burden change between DCB-treated lesion vs. medically-treated lesion.
ΔPlaque burden: IVUS-assessed changes in plaque burden between baseline and follow-up.
Time frame: 6~9 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.